Ulcerative colitis and perfluorooctanoic acid (PFOA) in a highly exposed population of community residents and workers in the Mid-Ohio Valley

Environmental Health Perspectives

Volumn 121, Issue 8, 2013, Pages 900-905

  Steenland, Kyle ^a   Zhao, Liping ^a   Winquist, Andrea ^a   Parks, Christine ^b  

^a EMORY UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Autoimmune; Inflammatory bowel disease; PFOA; Ulcerative colitis

Indexed keywords

PERFLUOROOCTANOIC ACID;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; BODY MASS; COMMUNITY CARE; CROHN DISEASE; DRUG EXPOSURE; ENTERITIS; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTERVIEW; LUPUS VULGARIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RESIDENT; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; ULCERATIVE COLITIS; WORKER;

ADULT; AGED; AGED, 80 AND OVER; CAPRYLATES; COLITIS, ULCERATIVE; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; FEMALE; FLUOROCARBONS; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE; OHIO; PREVALENCE; WATER POLLUTANTS, CHEMICAL; WEST VIRGINIA; YOUNG ADULT;

EID: 84880990984     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1206449     Document Type: Article

References (39)

1. Baumgart DC, Carding SR. 2007. Inflammatory bowel disease: cause and immunobiology. Lancet 369:1627-1640.
2. Bogdanos DP, Smyk DS, Rigopoulou EI, Mytilinaiou MG, Heneghan MA, Selmi C, et al. 2012. Twin studies in autoimmune disease: genetics, gender and environment. J Autoimmun 38:J156-J169.
3. C8 Science Panel. 2013. C8 Science Panel Homepage. Available: http:www.c8sciencepanel.org [accessed 18 June 2013].
4. Calafat AM, Wong LY, Kuklenyik Z, Reidy JA, Needham LL. 2007. Polyfluoroalkyl chemicals in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000. Environ Health Perspect 115:1596-1602.
5. Cooper GS, Bynum ML, Somers EC. 2009. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 33:197-207.
6. Davoli M, Prantera C, Berto E, Scribano ML, D'Ippoliti D. 1997. Mortality among patients with ulcerative colitis: Rome 1970-1989. Eur J Epidemiol 13:189-194.
7. DelgadoVega A, Sánchez E, Löfgren S, CastillejoLópez C, Alarcón-Riquelme ME. 2010. Recent findings on genetics of systemic autoimmune diseases. Curr Opin Immunol 22:698-705.
8. DeWitt JC, Copeland CB, Strynar MJ, Luebke RE. 2008 Perfluorooctanoic acidinduced immunomodulation in adult C57BL/6J or C57BL/6N female mice. Environ Health Perspect 116:644-650.
9. DeWitt JC, PedenAdams MM, Keller JM, Germolec DR. 2012. Immunotoxicity of perfluorinated compounds: recent developments Toxicol Pathol 40:300-311.
10. DeWitt JC, Shnyra A, Badr MZ, Loveless SE, Hoban D, Frame SR, et al. 2009. Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferatoractivated receptor alpha. Crit Rev Toxicol 39:76-94.
11. Dubuquoy L, Rousseaux C, Thuru X, PeyrinBiroulet L, Romano O, Chavatte P, et al. 2006. PPARg as a new therapeutic target in inflammatory bowel diseases. Gut 55:1341-1349.
12. Frisbee SJ, Brooks AP Jr, Maher A, Flensborg P, Arnold S, Fletcher T, et al. 2009. The C8 Health Project: design, methods, and participants. Environ Health Perspect 117:1873-1882.
13. Fromme H, Tittlemier SA, Volkel W, Wilhelm M, Twardella D. 2009. Perfluorinated compounds-exposure assessment for the general population in Western countries. Int J Hyg Environ Health 212:239-270.
14. Gersemann M, Wehkamp J, Stange EF. 2012. Innate immune dysfunction in inflammatory bowel disease. J Intern Med 271:421-428.
15. Grandjean P, Andersen EW, BudtzJørgensen E, Nielsen F, Mølbak K, Weihe P, et al. 2012. Serum vaccine antibody concentrations in children exposed to perfluorinated compounds. JAMA 307:391-397.
16. Hanauer SB. 2006. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 12(suppl 1):S3-S9.
17. Kappelman MD, Moore KR, Allen JK, Cook SF. 2013. Recent trends in the prevalence of Crohn's Disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci 58(2):519-525.
18. Lau C, Anitole K, Hodes C, Lai D, PfahlesHutchens A, Seed J. 2007. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci 99:366-394.
19. Leonard RC, Kreckmann KH, Sakr CJ, Symons JM. 2008. Retrospective cohort mortality study of workers in a polymer production plant including a reference population of regional workers. Ann Epidemiol 18:15-22.
20. Lindstrom AB, Strynar MJ, Libelo EL. 2011. Polyfluorinated compounds: past, present, and future. Environ Sci Technol 45:7954-7961.
21. Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. 2006. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc 81:1462-1471.
22. Mannon P, Reinisch W. 2012. Interleukin 13 and its role in gut defence and inflammation. Gut 61:1765-1773.
23. Miller FW, Alfredsson L, Costenbader KH, Kamen DL, Nelson LM, Norris JM, et al. 2012. Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop. J Autoimmun 39(4):259-271.
24. Olsen GW, Burris JM, Ehresman DJ, Froehlich JW, Seacat AM, Butenhoff JL, et al. 2007. Halflife of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect 115:1298-1305.
25. Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. 2012. Ulcerative colitis. Lancet 380:1606-1619.
26. Qazi MR, Bogdanska J, Butenhoff JL, Nelson BD, DePierre JW, AbediValugerdi M. 2009. Highdose, shortterm exposure of mice to perfluorooctanesulfonate (PFOS) or perfluorooctanoate (PFOA) affects the number of circulating neutrophils differently, but enhances the inflammatory responses of macrophages to lipopolysaccharide (LPS) in a similar fashion. Toxicology 262:207-214.
27. Sands BE. 2004. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 126:1518-1532.
28. Shin HM, Vieira VM, Ryan PB, Detwiler R, Sanders B, Steenland K, et al. 2011a. Environmental fate and transport modeling for perfluorooctanoic acid emitted from the Washington Works Facility in West Virginia. Environ Sci Technol 45:1435-1442.
29. Shin HM, Vieira VM, Ryan PB, Steenland K, Bartell SM. 2011b. Retrospective exposure estimation and predicted versus observed serum perfluorooctanoic acid concentrations for participants in the C8 Health Project. Environ Health Perspect 119:1760-1765.
30. Steenland K, Fletcher T, Savitz DA. 2010. Epidemiologic evidence on the health effects of perfluorooctanoic acid (PFOA). Environ Health Perspect 118:1100-1108.
31. Steenland K, Jin C, MacNeil J, Lally C, Ducatman A, Vieira V, et al. 2009. Predictors of PFOA levels in a community surrounding a chemical plant. Environ Health Perspect 117:1083-1088.
32. Steenland K, Woskie S. 2012. Mortality patterns among workers exposed to PFOA. Am J Epidemiol 176:909-917.
33. Strynar MJ, Lindstrom AB. 2008. Perfluorinated compounds in house dust from Ohio and North Carolina, USA. Environ Sci Technol 42:3751-3756.
34. Takacs ML, Abbott BD. 2007. Activation of mouse and human peroxisome proliferator-activated receptors (a, b/d, g) by perfluorooctanoic acid and perfluorooctane sulfonate. Toxicol Sci 95:108-117.
35. Vanden Heuvel JP, Thompson JT, Frame SR, Gillies PJ. 2006. Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-a,-b, and-g, liver X receptor-b, and retinoid X receptor-a. Toxicol Sci 92:476-489.
36. Winquist A, Lally C, Shin HM, Steenland K. 2013. Design, methods and population for a study of PFOA health effects among highly exposed MidOhio Valley community residents and workers. Environ Health Perspect 121:893-899.
37. Winther KV, Jess T, Langholz E, Munkholm P, Binder V. 2003. Survival and causespecific mortality in ulcerative colitis: followup of a populationbased cohort in Copenhagen County. Gastroenterology 125:1576-1582.
38. Woskie SR, Gore R, Steenland K. 2012. Retrospective exposure assessment of perfluorooctanoic acid serum concentrations at a fluoropolymer manufacturing plant. Ann Occup Hyg 56:1025-1037.
39. Yang Q, Xie Y, DePierre JW. 2000. Effects of peroxisome proliferators in the thymus and spleen of mice. Clin Exp Immunol 122:219-226.